NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES

摘要

Use of a pyridothienopyrimidine derivative of formula (I), and the pharmaceutically acceptable salts and N-oxides thereof, wherein G<SUP>1</SUP> represents a group selected from -CR<SUP>6</SUP>R<SUP>7</SUP>- or -NR<SUP>6</SUP> being R<SUP>6</SUP> and R<SUP>7 </SUP>independently selected from hydrogen atoms and C<SUB>1-4 </SUB>alkyl groups m and n are integers selected from 0 or 1 R<SUP>1</SUP> and R<SUP>2</SUP> are independently selected from hydrogen atoms and C<SUB>1-4 </SUB>alkyl groups R<SUP>3</SUP> represents a group selected from alkyl, amino, monoalkylamino, dialkylamino, aryl, heteroaryl and saturated N-containing heterocyclyl groups bound through the nitrogen atom to the piridine ring, all of them being optionally substituted by one or more substituents selected from the group consisting of halogen atoms and alkyl, alkoxyalkyl, arylalkyl, R<SUP>8</SUP>OCO-, alkoxy, R<SUP>8</SUP>R<SUP>9</SUP>N-CO-, -CN, -CF<SUB>3</SUB>, -NR<SUP>8</SUP>R<SUP>9</SUP>, -SR<SUP>8</SUP> and - SO<SUB>2</SUB>NH<SUB>2</SUB> groups wherein R<SUP>8</SUP> and R<SUP>9</SUP> are independently selected from hydrogen atoms and C<SUB>1-4</SUB>alkyl groups R<SUP>4</SUP> and R<SUP>5</SUP> are independently selected from the group consisting of hydrogen atoms alkyl groups and groups of formula (II), wherein p and q are integers selected from 1, 2 and 3; A is either a direct bond or a group selected from -CONR<SUP>14</SUP>-, -NR<SUP>14</SUP>CO-, -O-, -COO-, -OCO-, -NR <SUP>14</SUP>OCO-, - OCONR<SUP>14</SUP>-, -NR<SUP>14</SUP>CONR<SUP>15</SUP>-, -S-, -SO-, -SO<SUB>2</SUB>-, -COS- and -SCO-; and G<SUP>2</SUP> is a group selected from aryl, heteroaryl or heterocyclyl; wherein the alkyl groups and the group G<SUP>2</SUP> are optionally substituted by one or more substituents selected from group consisting of halogen atoms and alkyl, alkoxyalkyl, arylalkyl, R<SUP>16</SUP>OCO-, hydroxy, alkoxy, oxo, R<SUP>16</SUP>R<SUP>17</SUP>NCO-, -CN, -CF<SUB>3</SUB>, -NR<SUP>16</SUP>R<SUP>17</SUP>,<SUP/>-SR<SUP>16</SUP> and -SO<SUB>2</SUB>NH<SUB>2</SUB> groups; wherein R<SUP>10 </SUP>to R<SUP>17 </SUP>are independently selected from hydrogen atoms and C<SUB>1-4 </SUB>alkyl groups; in the manufacture of a medicament for the treatment or prevention of a pathological condition or disease susceptible to amelioration by inhibition of phosphodiesterase 4.